15 April 2025
EMTN Program Documents
Documents
DSM BV Annual Report 2022 and 2023
Danube AG financial statements
DSM-Firmenich AG Annual Report 2023
Articles of Association of DSM BV
Articles of Association of DSM-Firmenich AG
Base Prospectus
Cross Guarantee Agreement
Final Terms of EUR 800m bond was issued on July 2, 2024
Supplement
Final Terms of 11YR, EUR 750m bond issued on February 25, 2025
Latest news
-
-
8 April 2025
Weekly progress on share repurchase program to cover share plans and reduce capital
-
8 April 2025
Laetitia Pictet appointed Chief Legal, Risk and Compliance Officer of dsm-firmenich
-
3 April 2025
dsm-firmenich completes shareholding increase in Andre Pectin to 90.5%
-
1 April 2025
dsm-firmenich announces share repurchase program to cover share plans and reduce capital
-
25 March 2025
dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day
-
28 February 2025
dsm-firmenich publishes 2024 Integrated Annual Report
-
19 February 2025
dsm-firmenich issues €750 million long-term bond
-
13 February 2025
dsm-firmenich reports full year 2024 results
-
11 February 2025
dsm-firmenich to sell stake in Feed Enzymes Alliance to its partner Novonesis for €1.5 billion
-
21 November 2024
DSM-Firmenich AG sold all of its stake in Robertet S.A.
-
15 November 2024
DSM-Firmenich AG sold the majority of its stake in Robertet S.A.
-
14 November 2024
DSM-Firmenich AG to sell part of its stake in Robertet S.A.
-
31 October 2024
dsm-firmenich Q3 2024 trading update
-
24 October 2024
dsm-firmenich receives validation from the Science Based Targets initiative for its 2045 net-zero targets
-
2 October 2024
dsm-firmenich completes the sale of yeast extract business to Lesaffre
-
1 October 2024
dsm-firmenich completes the sale of its MEG-3® fish oil business to KD Pharma Group SA
-
8 August 2024
dsm-firmenich concludes new €1.8 billion Revolving Credit Facility
-
30 July 2024
dsm-firmenich reports H1 2024 results
-
18 July 2024
dsm-firmenich to sell MEG-3® fish oil business to KD Pharma Group
-
26 June 2024
dsm-firmenich issues €800 million long-term bond
-
14 June 2024
DSM shareholders can voluntarily transfer their shares to dsm-firmenich before July 2, 2024, 17:45 hours CEST
-
12 June 2024
dsm-firmenich announces sale of yeast extract business to Lesaffre
-
3 June 2024
dsm-firmenich takes strategic actions to strengthen its position as a leading creation and innovation partner in Nutrition, Health and Beauty
-
31 May 2024
dsm-firmenich implements a cross guarantee agreement to mitigate structural subordination and establish a pari-passu debt platform
-
29 May 2024
Methane-reducing feed ingredient Bovaer® ready for US market launch
-
7 May 2024
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2024
-
7 May 2024
Share repurchase program to cover share plans completed
-
2 May 2024
dsm-firmenich Q1 2024 trading update
-
30 April 2024
dsm-firmenich's progress on share repurchase program to cover share plans
-
16 April 2024
dsm-firmenich completes on-market repurchase of 500,000 shares to cover share plans
-
8 April 2024
dsm-firmenich announces repurchase of 1.5m shares to cover share plans
-
8 March 2024
dsm-firmenich completes the divestiture of its Jiangshan Vitamin C plant in China
-
29 February 2024
dsm-firmenich publishes 2023 Integrated Annual Report
-
15 February 2024
dsm-firmenich reports 2023 full year results
-
14 February 2024
dsm-firmenich to separate out Animal Nutrition & Health business from the Group
-
12 February 2024
dsm-firmenich completes voluntary cash offer for DSM shares
-
8 January 2024
dsm-firmenich makes voluntary cash offer for DSM shares
-
31 October 2023
dsm-firmenich reports Q3 2023 results
-
10 October 2023
dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition
-
4 October 2023
dsm-firmenich provides additional pro forma financial information for 2022 and 2023
-
2 August 2023
dsm-firmenich reports H1 2023 results
-
3 July 2023
dsm-firmenich completes acquisition of postbiotics pioneer Adare Biome
-
29 June 2023
dsm-firmenich announces results of extraordinary general meeting of shareholders
-
28 June 2023
Trading update and acceleration of strategic actions
-
22 May 2023
Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich
-
17 May 2023
dsm-firmenich names Katharina Stenholm as Chief Sustainability Officer
-
9 May 2023
dsm-firmenich launches as innovators in nutrition, health, and beauty
-
9 May 2023
Completion of contribution of Firmenich shares
-
4 May 2023
dsm-firmenich announces evolution of CEO structure per 1 September, following completion of the merger
-
2 May 2023
DSM provides Q1 2023 trading update
-
1 May 2023
Final results of the exchange offer: 96.1% of DSM ordinary shares tendered
-
18 April 2023
dsm-firmenich first day of trading on Euronext Amsterdam
Explore more
-
Investors
Two global leaders in science and innovation have joined forces to become dsm-firmenich, creating a world of potential for investors.
-
Financial calendar
A handy overview of the key dates in our financial calendar.
-
Share center
All the key details on holding and trading shares of dsm-firmenich.